NASDAQ: FULCFulcrum Therapeutics Inc Stock
$3.45-0.10 (-2.82%)
Updated Jun 12, 2026
FULC Price
$3.45
Fair Value Price
$3.02
Market Cap
$229.88M
52 Week Low
$2.91
52 Week High
$15.74
P/E
-3x
P/B
0.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$76.12M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.04
Operating Cash Flow
-$64M
Beta
1.27
Next Earnings
Jul 29, 2026
Ex-Dividend
N/A
Next Dividend
N/A
FULC Overview
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs. Its leading investigational therapies include losmapimod, a small molecule targeting facioscapulohumeral muscular dystrophy, and FTX-6058, an orally administered fetal hemoglobin inducer for sickle cell disease and related hemoglobinopathies, such as beta-thalassemia. Beyond these, Fulcrum is actively engaged in discovering new drug targets for various rare conditions, encompassing neuromuscular, muscular, central nervous system, and hematologic disorders, alongside cardiomyopathies and pulmonary diseases. The company has established key collaborations, notably a research and discovery partnership with Acceleron Pharma Inc. to identify biological targets within the pulmonary disease area, and a strategic licensing and development agreement with MyoKardia, Inc. focused on novel targeted therapies for genetic cardiomyopathies. Incorporated in 2015, Fulcrum Therapeutics, Inc. maintains its headquarters in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FULC's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
FULC
Ranked#308 of 463
Ranked#308 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important FULC news, forecast changes, insider trades & much more!
FULC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FULC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FULC ($3.45) is overvalued by 14.38% relative to our estimate of its Fair Value price of $3.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
FULC ($3.45) is not significantly undervalued (14.38%) relative to our estimate of its Fair Value price of $3.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
FULC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FULC due diligence checks available for Premium users.
Valuation
FULC fair value
Fair Value of FULC stock based on Discounted Cash Flow (DCF)
Price
$3.45
Fair Value
$3.02
Overvalued by
14.38%
FULC ($3.45) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FULC ($3.45) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FULC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FULC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3x
Industry
16.53x
Market
14.15x
FULC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.69x
Industry
4.85x
FULC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FULC's financial health
Profit margin
Revenue
$0.0
Net Income
-$18.9M
Profit Margin
0%
FULC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$346.8M
Liabilities
$13.5M
Debt to equity
0.04
FULC's short-term assets ($338.67M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FULC's short-term assets ($338.67M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FULC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FULC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$18.8M
Investing
-$128.2M
Financing
-$312.0k
FULC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FULC vs Biotech Stocks
Fulcrum Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.